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Introduction
Neglected tropical diseases (NTD) are a group of 17 highly de-
bilitating and potentially fatal poverty-related diseases. These
include protozoan, bacterial, and helminthic infections that
prevail in tropical and subtropical areas in 149 countries. Com-
munities living in poverty, lacking access to basic sanitation
and in close contact with infectious disease vectors, domestic
animals and livestock, are those worst affected.[1] Notwith-
standing the recent re-emergence of interest in NTD, continu-
ous research efforts are needed to sustain any drug develop-
ment pipeline in the medium and long term.[2]
Human African trypanosomiasis (HAT) is one of the most ne-
glected tropical diseases, endemic in sub-Saharan Africa. Trypa-
nosoma brucei rhodesiense (East and Southern Africa) and
T. b. gambiense (West and Central Africa) are the causative pro-
tozoan parasites, which are transmitted to humans by tsetse
flies that are found only in Africa.[3] This disease, which is disa-
bling and fatal if left untreated, is a major cause of rural under-
development and severely affects economies and communi-
ties. The control and elimination of HAT, which are declared
goals of the WHO,[1] would be a major step in the reduction of
the overall burden of tropical disease that continues to limit
development in sub-Saharan Africa.[4] Although HAT transmis-
sion is limited to the tsetse belt, comprising much of sub-Sa-
haran Africa, the risk of HAT in travelers and migrants, albeit
low, cannot be overlooked.[5] Moreover, animal African trypano-
somiasis (AAT) has an enormous impact on African agriculture
and food security. This condition is caused by related trypano-
some species including T. b. brucei, T. congolense, T. evansi, and
T. vivax, and, not necessarily being dependent on tsetse flies,
has spread to much of South America, South Asia, and the
Middle East.[6]
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In the search for effective and sustainable drugs for human Af-
rican trypanosomiasis (HAT), we developed hybrid compounds
by merging the structural features of quinone 4 (2-phenoxy-
naphthalene-1,4-dione) with those of phenolic constituents
from cashew nut shell liquid (CNSL). CNSL is a waste product
from cashew nut processing factories, with great potential as a
source of drug precursors. The synthesized compounds were
tested against Trypanosoma brucei brucei, including three mul-
tidrug-resistant strains, T. congolense, and a human cell line.
The most potent activity was found against T. b. brucei, the
causative agent of HAT. Shorter-chain derivatives 20 (2-(3-(8-hy-
droxyoctyl)phenoxy)-5-methoxynaphthalene-1,4-dione) and 22
(5-hydroxy-2-(3-(8-hydroxyoctyl)phenoxy)naphthalene-1,4-
dione) were more active than 4, displaying rapid micromolar
trypanocidal activity, and no human cytotoxicity. Preliminary
studies probing their mode of action on trypanosomes
showed ATP depletion, followed by mitochondrial membrane
depolarization and mitochondrion ultrastructural damage. This
was accompanied by reactive oxygen species production. We
envisage that such compounds, obtained from a renewable
and inexpensive material, might be promising bio-based sus-
tainable hits for anti-trypanosomatid drug discovery.
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HAT treatment today relies on five drugs (pentamidine
(PMD), suramin, melarsoprol, nifurtimox, and eflornithine; see
Supporting Information Figure S1 for chemical structures),
which suffer from toxic side effects, lack of efficacy, and devel-
opment of resistance.[1] The management of patients using
these drugs is complex and risky, requiring the support serv-
ices of a well-trained staff.[7] Moreover, despite the fact that
almost all HAT control programs subsidize the cost of drugs
and hospitalization,[8] the availability of quality medicinal
agents on a sustainable basis is an increasingly appreciated
public health care concept. Consequently, lowering the costs
of therapy by developing new drugs based on inexpensive re-
sources is a valuable approach to be pursued.
Based on the above considerations, as well as on our contin-
uous interest in the NTD field, we explored the possibility of
using cashew nut shell liquid (CNSL) as a sustainable, low-cost
starting material for the development of new drugs against
trypanosomiases. CNSL, which is obtained as the by-product of
cashew nut processing, has proven to be one of the most ver-
satile food wastes for the production of functional materials
and chemicals.[9] However, its potential as a precursor of drugs
has been relatively underexplored. Being an inedible waste
material, it presents clear environmental, financial and ethical
advantages over synthetic drugs and even over natural prod-
ucts derived from crops grown for that purpose.[10] In addition,
the fact that East Africa (Tanzania, Kenya, and Mozambique)
and West Africa (Benin, Guinea-Bissau, Ivory Coast, and Nigeria)
are among the largest CNSL-producing countries, opens up
the exciting possibilities to engage endemic countries as cru-
cial actors in NTD drug discovery and development.[11] On this
basis, we have developed a new chemical library of CNSL-de-
rived hybrids and investigated their anti-trypanosomal poten-
tial. In particular, the compounds were evaluated against wild-
type (WT) and multidrug-resistant African trypanosomes;
T. b. brucei is extremely closely related to the human-infectious
species, and T. congolense is the principal agent causing AAT in
Africa. Some of the compounds displayed low micromolar ac-
tivity against T. b. brucei and absence of toxicity on a human
cell line. We therefore investigated the mechanism by which
this compound class exerts its trypanocidal activity.
Results and Discussion
Design rationale
CNSL mainly consists of phenolic lipids, that is, anacardic acids
(1 in Figure 1) (71.7%), cardanols (2) (4.7%), and cardols
(18.7%) (3).[12] The pentadecyl alkyl side chain of 1–3 may be
saturated, mono-olefinic, di-olefinic or tri-olefinic with a high
percentage of the components having one or two double
bonds (Figure 1), depending on the production method.[12] Al-
though CNSL components have been reported to possess a
wide range of biological activities, in many cases they are not
potent enough to be drug candidates.[9] To overcome this limi-
tation, their use in combination with standard drugs, and the
design of new semi-synthetic derivatives have been exploit-
ed.[9]
Along these lines, we decided to develop a series of CNSL-
based hybrid compounds. In particular, building on the strat-
egy that the combinations of two different fragments into one
covalently linked hybrid compound can convey synergy and
increase potency,[13] we combined the chemical features of
CNSL derivatives with those of a previously developed anti-try-
panosomal hit compound (4 in Figure 2).[14] Intriguingly, both
4[14b] and a mixture of anacardic acids,[15] isolated from Brazilian
CNSL, have been reported to inhibit trypanosomal glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), an essential glyco-
lytic enzyme and a validated anti-trypanosomatid target.[16]
Furthermore, thanks to the presence of a naphthoquinone
moiety, 4 was shown to generate reactive oxygen species
(ROS), a mechanism that may further contribute to its multi-
target trypanocidal activity.[14b] In fact, 4 exhibited high poten-
Figure 1. The main components of CNSL.
Figure 2. Design strategy to generate CNSL-based hybrids 8–22 (see
Scheme 1 for structures).
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cy against T. b. rhodesiense (STIB 900 strain) (IC50=80 nm) and a
promising selectivity index (SI) of 74, with respect to L6 mam-
malian cells.[14a] In particular, we anticipated that overlapping 4
with CNSL derivatives 5 and 6 (Figure 2) through their
common phenoxy moiety could lead to hybrids with an im-
proved anti-trypanosomal profile and an improved sustainabili-
ty. In addition, considering that the presence of the long alkyl
chain (C15) might limit drug-likeness due to excessive lipophilic-
ity (see predicted physicochemical properties in Table 1 and
S1) and might give rise to surfactant properties and nonspecif-
ic activities, we also turned our attention to the shorter-chain
(C8) CNSL derivative 7. Following this design strategy, the small
combinatorial library of 8–22 was generated (Figure 2 and
Scheme 1).
Synthetic strategies for CNSL-based hybrids (8–22) and
CNSL-phenols (5–7)
The synthesis of 8–22 was performed as illustrated in
Scheme 1. We exploited a previously developed one-pot reac-
tion to combine phenols 5–7 and 2-bromo-1,4-naphtoqui-
nones 23–27.[14a,c] Phenols 5–7 were first treated with K2CO3 at
room temperature in DMF, and then the proper 2-bromo-1,4-
naphtoquinone (23–27) was added, to rapidly (2–3 h) afford
final compounds 8–22. Despite its utility in nucleophilic substi-
tution reaction, DMF is clearly not compatible with the current
drive toward more sustainable and environmental friendly me-
dicinal chemistry processes.[17] With this in mind, we substitut-
ed DMF, which has been categorized as a hazardous solvent,
with the safer DMSO.[18] Encouragingly, similar yield were ob-
tained (see Experimental Section). 2-Bromo-1,4-naphthoqui-
none 23 was commercially available, whereas methoxy- and
hydroxy-naphthoquinones 24–27 were prepared as previously
reported.[19]
On the other hand, the CNSL-based phenols 5–7 have been
synthesized starting from the cashew nut shells. Particularly, to
synthesize phenol 5, an extraction of 150 g of cashew nut
shells with ethanol yielded 60 g of natural CNSL (40 wt%
based on the nut shells). The acids were then separated from
other phenolic components by precipitation of their calcium
salts using calcium hydroxide followed by acidification, which
led to 21 g (70 wt% based on 30 g of the alcoholic extract) of
the acid mixture 1. Next, hydrogenation of 1 using palladium
Table 1. EC50 values [mm] against trypomastigotes of T. b. brucei (T. b. b.), T. congolense (T. c.), and HFF cells, along with selectivity indexes, resistance factors,
and predicted logP values for compounds 8–22.
Compd T. b. b.
427WT
SI[a] T. b. b.
B48
RF[b] T. b. b.
aqp2/aq3-KO
RF[b] T. c.
IL3000WT
HFF[c] logP[d]
8 >200 n.d. n.d. n.d. n.d. 10.88
9 >200 n.d. n.d. n.d. n.d. 10.85
10 >200 n.d. n.d. n.d. n.d. 10.85
11 >200 n.d. n.d. n.d. n.d. 11.07
12 >200 n.d. n.d. n.d. n.d. 11.07
13 >200 n.d. n.d. n.d. n.d. 10.75
14 >200 n.d. n.d. n.d. n.d. 11.0
15 >200 n.d. n.d. n.d. n.d. 11.0
16 >200 n.d. n.d. n.d. n.d. 11.22
17 >200 n.d. n.d. n.d. n.d. 11.22
18 9.1:1.4 >21.98 8.6:2.4 0.95 10.1:2.2 1.1 n.d. n.e. 5.64
19 15.0:1.3 >13.3 14.6:1.7 0.98 17.7:1.5 1.2 n.d. n.e. 5.62
20 5.0:0.3 >40 5.3:0.8 1.1 6.2:0.58 1.2 18.8:0.2 n.e. 5.62
21 40.5:4.9 >5 36.9:5.3 0.91 46.7:7.7 1.2 n.d. n.e. 5.84
22 7.6:0.7 >26.3 6.8:0.1 0.91 7.3:0.5 0.96 43.4:0.2 n.e. 5.84
4 48.7:0.8 n.d. 63.0:0.4 1.3 62.4:0.8 1.3 108:2 n.d.[g] n.d.
PMD[e] 0.0093:0.0001 3.1:0.7 339 0.20:0.01 22.0 n.d. n.d. n.d.
DA[f] n.d. n.d. n.d. 0.17:0.0003 n.d. n.d.
None of the EC50 values for the test compounds against the T. b. b. 427WT strain were significantly different in the B48 or aqp2/aqp3-KO strains. In contrast,
the EC50 value for pentamidine (PMD) was highly significantly different in the latter two strains relative to 427WT (p<0.001, Student’s unpaired t-test, n=4
for all data points) ; n.d. : not determined; n.e. : no effect at 200 mm. [a] Selectivity index=EC50(HFF)/EC50(T. b. b. WT). [b] Resistance factor relative to WT.
[c] Cytotoxic activity (EC50) on human foreskin fibroblast (HFF) cells; cytotoxic activity was observed up to 200 mm. [d] logP values were predicted with FAF-
Drugs4 software (http://fafdrugs3.mti.univ-paris-diderot.fr). [e] Pentamidine. [f] Diminazene aceturate. [g] The EC50 value of 4 is 9.84:3.25 against human
dermal fibroblasts (HDF).[14c]
Scheme 1. Synthesis of target compounds 8–22 : i) K2CO3, DMF, RT, 3%–65%.
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on carbon as catalyst allowed affording 28 in 70% yield
(Scheme 2).
Subsequently, 28 is converted into its corresponding methyl
ester 5, by performing a classical esterification reaction (H2SO4
in methanol). Toward the synthesis of CNSL-based phenols 6
and 7, our approach was based on distilled technical CNSL.
Commercially available technical CNSL is obtained by treating
hydrated shells at temperatures around 180–210 8C, and con-
tains mainly the mixture of cardanols (2)—by decarboxylation
of the anacardic acids (1)—and cardols (3). Distillation of the
technical CNSL led to a heterogeneous mixture of cardanols 2,
as the primary component of CNSL. Hydrogenation of 2 using
palladium on carbon as catalyst led to the saturated cardanol
6 in 90% yield (Scheme 3). Conversely, compound 7 was syn-
thesized using a three-step protocol : a) protection of the
phenol group by acetylation of 2, b) oxidative cleavage by ozo-
nolysis, c) reduction of the resulting secondary ozonide to the
corresponding alcohol with sodium borohydride (Scheme 3).
In vitro activity against T. b. brucei wild-type and resistant
strains and T. congolense wild-type strain
The parent compound 4 and the CNSL-based hybrid deriva-
tives 8–22 were tested for effects on cell viability against
bloodstream trypomastigotes of the standard drug-sensitive
T. b. brucei strain 427WT. The most active compounds were fur-
ther tested against the multidrug-resistant strain B48 and the
drug-transporter deletion mutant aqp2/aqp3-KO (Table 1). The
current first-line drug PMD was used as the reference com-
pound. It should be noted that the EC50 values reported herein
were produced using a different species (T. b. brucei versus
T. b. rhodesiense) and a different resazurin-based protocol from
that used in the previous report,[14a] in which the EC50 value of
4 against T. b. rhodesiense was found to be 80 nm. The very
robust protocol used here uses a much higher cell density and
consequently results in substantially higher EC50 values.
[20]
Using this protocol, only compounds 18–22, which carry the
shorter (C8) aliphatic chain, showed anti-trypanosomal activity
in the micromolar range (5.0–40.5 mm). Importantly, under
these conditions, 18–22 had higher activity than 4, which dis-
plays an EC50 value of 48.7 mm. Crucially, compounds 18–22
showed no sign of human cytotoxicity : none of the com-
pounds displayed any effects on either the viability or growth
of the human foreskin fibroblast (HFF) cell line at the highest
tested concentration (200 mm). Notably, 18–22 displayed statis-
tically identical activity (p>0.05) against the aqp2/aqp3-KO
cell line from which the well-characterized drug transporter
HAPT1/TbAQP2 has been deleted,[21] resulting in a moderated
level of PMD resistance (Table 1). Indeed, there was no cross-re-
sistance detected even in the very highly multidrug-resistant
cell line B48, although it displayed 178-fold resistance to PMD
in this series of experiments (Table 1). Interestingly, compounds
18–22 were up to 12-fold more active against all strains than
the starting compound 4, suggesting an improvement of the
activity in at least some of the newly synthetized CNSL-based
hybrids. This shows that the shorter alkyl chain with a primary
alcoholic end function, together with the regioisomeric substi-
tution on the naphthoquinone moiety, enhances the anti-try-
panosomal activity of the test compounds (see below).
The two most active compounds 20 and 22 and the parent
compound 4 were also tested against T. congolense IL3000 cell
line and compared with the standard drug against animal try-
panosomiasis, diminazene aceturate (DA in Supporting Infor-
mation Figure S1). All three compounds were less active than
DA, with EC50 values in the mid-to-high micromolar range, as
well as severalfold less active than against T. brucei. Despite the
small number of compounds tested, the results with T. congo-
lense suggest that this species may be systematically less sensi-
tive to this scaffold than T. brucei is. Similarly, T. congolense is
less sensitive than T. brucei to suramin[6] and PMD,[22] reflecting
species differences in drug target or accumulation.
Structure–activity relationship (SAR) of trypanocidal activity
Our goal was to design and synthetize a small library of CNSL-
based hybrids, aiming for a synergistic inhibition of energy me-
tabolism in T. b. brucei, targeting mitochondrial functions and
GAPDH inhibition. Along the line of this rationale, we designed
the library of CNSL-based hybrids starting from quinone 4 and
longer (5 and 6) and shorter (7) CNSL derivatives. Intriguingly,
only C8 compounds 18–22 showed a promising anti-trypano-
somal activity, whereas 8–17 (C15) were not effective up to a
concentration of 200 mm. Notably, a significantly higher efficacy
was detected for 18–22 in comparison with 4, suggesting that,
at least for this subset, the proposed hybridization strategy
was successful. As expected by the predicted logP values
(Table 1), the nature of the chain dramatically affected activity,
probably by modulating cell partitioning. This might be due to
the insertion of the alkyl chain on the phenoxy ring that might
positively modulate the lipophilicity of the test compounds in-
creasing cell viability. In fact, significant differences can be ap-
preciated among the longer- and the shorter-chain subsets :
Scheme 2. Synthesis of phenol 5 : i) H2, Pd/C, EtOH, RT, 70%; ii) H2SO4,
CH3OH, reflux, 86%.
Scheme 3. Synthesis of phenols 6–7: i) H2, Pd/C, EtOH, RT, 90%; ii) (a) Ac2O,
H3PO4, MW, 400 W, 73%, (b) O3, (CH3)2CO, @78 8C, (c) NaBH4, CH3OH, RT, 79%.
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the CNSL-based derivatives 8–12 and 13–17 showed no anti-
trypanosomal activity against T. b. brucei up to 200 mm.
Anti-trypanosomal profile and time-to-kill determination
To determine whether 18–22 inhibited growth or cell division
rather than causing cell death of T. b. brucei, cell growth curves
were performed by treating 427WT trypomastigotes with con-
centrations corresponding to 0.5V , 1V , and 2V the EC50 value,
using untreated cells as a control. Incubation with test com-
pounds at half the EC50 (Figure 3A) caused mostly some de-
layed growth phenotype, with rates increasing after 10 or 20 h.
At 1V their respective EC50 (Figure 3B), the hybrid compounds
induced a consistent, rapid-onset decrease in cell growth rate
over 48 h. Compounds 18 and 19 showed trypanocidal activity
at this concentration, sterilizing the culture in 2 and 8 h, re-
spectively. Compound 22 appeared similarly to rapidly de-
crease the cell density but, at this concentration, killed only a
proportion of the cell population before stabilizing; 20 and 21
decreased the growth rate substantially, with a nearly trypano-
static effect over the first 12 h (Figure 3B). At double the con-
centration (Figure 3C), all the hybrids cleared the culture be-
tween the 4 h and 8 h time points, with the cell populations
rapidly declining between 2 and 4 h. The rapid time to kill dis-
played by 18–22 (and the lack of cross-resistance with existing
chemotherapy) is a clear advantage toward any (pre)-clinical
development of this scaffold, and encourages further hit opti-
mization efforts.
Activity of the compounds against T. brucei GAPDH
Based on the reported activity of starting compound 4, which
displays an IC50 of 7.25 mm against GAPDH,
[14b] we first tested
inhibition of this enzyme by 8–22, at a fixed concentration of
10 mm, following a previously reported protocol.[14c] However,
none of the compounds displayed significant inhibition of
GAPDH activity (<15% decrease observed, data not shown).
One explanation for this lack of inhibitory activity might be
that the current series of hybrids is partially or completely pre-
vented from binding the active site of the trypanosomal glyco-
lytic enzyme because of steric hindrance by the long alkyl
chain. Limitations of solubility prevented us from testing the
series at higher concentrations. However, it must be noted
that we cannot exclude the possibility of a low-affinity inhibi-
tion of GAPDH contributing to the trypanocidal effect, as com-
pounds may accumulate to relatively high concentrations
within the parasite. Indeed, examples where a high level of ac-
cumulation include almost all the first-line trypanocidal agents
(Supporting Information Figure S1), including DA,[23] PMD,[24]
melarsoprol,[25] and suramin[26] and highly active experimental
therapies, including a recently described series of bisphospho-
nium compounds[27] that strongly accumulate in the T. b. brucei
mitochondrion.
Mode of action studies
Because the drug design of our series of hybrids is based on
the naphthoquinone framework that is recognized as a privi-
leged structure for the modulation of the mitochondrial func-
tions[28] and 4 itself acted at mitochondrial targets through
production of ROS,[14b] we had reason to further investigate
their mode of action at the mitochondrial level in T. b. brucei.
Furthermore, the chemical structures of the newly CNSL-based
hybrids resemble that of ubiquinone (Supporting Information
Figure S2), which is an essential carrier in the electron-trans-
port chain via a redox reaction inner the mitochondrial mem-
brane. Accordingly, we initially aimed for a synergistic inhibi-
tion of the energy metabolism for our hybrids, targeting the
mitochondrial membrane enzymes involved in electron trans-
port (e.g. , trypanosome alternative oxidase (TAO), FoF1-H
+
ATPase), in addition to glycolysis (GAPDH, located in the glyco-
some).[29] This because inhibition of both of the essential arms
of trypanosomal energy metabolism would be expected to de-
liver synergistic effects. Despite the fact that we were not able
to demonstrate a GAPDH inhibitory activity of our hybrids, we
looked at the effects of the two most active compounds 20
and 22 on ATP content and on the mitochondrial membrane
potential (MMP), as relevant parameters for an action on the
trypanosomal energy metabolism.[30]
Figure 3. Cell counts of T. b. brucei cultures (bloodstream trypomastigotes),
seeded at 1V105 cellsmL@1, incubated in the presence of either A) 0.5V ,
B) 1V , or C) 2V the EC50 of the test compounds. Where the lines stop, no
live cells were detected at the next time point. Error bars represent SEM;
where they are not shown, they are obscured by the symbols.
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ATP and MMP determination as relevant evidence for a
mitochondrial mode of action
T. b. brucei 427WT BSF were incubated with 20 and 22, at ap-
proximately 0.5VEC50, and the ATP content was determined at
different time points (Figure 4). The FoF1-ATPase inhibitor oligo-
mycin (see Supporting Information Figure S2 for structure) was
used as positive control and untreated cells as negative con-
trol. We found that both compounds rapidly decrease the ATP
content, with even 30 min inducing a highly significant reduc-
tion in cellular ATP levels (p<0.01), stabilizing at approximately
50% of untreated [ATP] after 4–6 h (p<0.001). The response to
20 and 22 was similar not just to each other, consistent with
an identical mode of action, but also highly similar to that of
oligomycin, although the latter depressed the ATP levels even
further at the respective concentrations used (Figure 4). It
should be noted that the observed decrease in ATP does not
correlate with cell death, which even at 2VEC50 does not occur
in large number until after 4 h. The observed decrease in ATP
levels could be the result of mitochondrial functions and there-
fore we next investigated the timing of the same concentra-
tions of 20 and 22 on the mitochondrial membrane potential
Ym, using flow cytometry with the fluorescent probe TMRE. Va-
linomycin (Supporting Information Figure S2) was used as the
control for depolarization and troglitazone (Supporting Infor-
mation Figure S2), as the control for hyperpolarization
(Figure 5).[31]
Both test compounds decreased Ym slightly over the first
hour (p>0.05), an effect that was stronger at the 4 h (p<0.05
for 20) and subsequent time points (p<0.01 for both com-
pounds). The Ym is expressed as the percentage of cells dis-
playing a fluorescence of +500 arbitrary units (calibrated at
50% for untreated cells at t=0), with a shift toward lower fluo-
rescence indicating a mitochondrial membrane depolarization
(Supporting Information Figure S3). It is clear from the time de-
pendency and magnitude of the effects that cellular ATP de-
pletion preceded the partial depolarization of the mitochondri-
al inner membrane. We thus conclude that the depolarization
is likely to be the result of the decreased availability of ATP for
the FoF1-ATPase, which maintains the membrane potential of
the mitochondrion of bloodstream T. brucei, using the ATP to
pump protons out of the mitochondrial matrix.[32] The primary
cause of the ATP depletion may be the inhibition of an essen-
tial mitochondrial function, and/or a step in the glycolysis.
However, we re-tested compounds 18, 19, 20 and 22
against 427WT cells, in the presence and absence of 5 mm
glycerol in the medium, an addition that sensitizes the cells to
TAO inhibitors such as salicylhydroxamic acid (SHAM) and asco-
furanone (Supporting Information Figure S2).[33] Indeed, we
found that the cells were significantly sensitized to SHAM in
the presence of glycerol (p<0.001), but not to the hybrid com-
pounds (Table 2). Interestingly, compound 20 displayed signifi-
cantly (p<0.001) less activity in the presence of glycerol,
whereas the EC50 values for the other test compounds was un-
changed. We conclude that 18, 19, 20 and 22 do not act via
direct inhibition of TAO.
CNSL-based hybrids increase the production of reactive
oxygen species (ROS) in T. b. brucei
To determine whether our hybrids display a redox activity in
T. b. brucei 427WT BSF (similarly to what has been demonstrat-
ed for 4),[14b] we assessed the production of ROS in cells treat-
ed with 20 and 22 and in control cells, using the ROS-sensitive
Figure 4. ATP content of bloodstream trypomastigotes of T. b. brucei 427WT
after incubation with oligomycin (2.0 mgmL@1 &), 20 (2.2 mm !), 22 (3.5 mm
~) or no drug (control *). Data are the average:SEM of three determina-
tions.
Figure 5. Mitochondrial membrane potential Ym in bloodstream trypomasti-
gotes of T. b. brucei 427WT was determined at various time points after incu-
bation with various test compounds: troglitazone (10 mm &), valinomycin
(0.1 mm ~), 20 (2.4 mm ! ), 22 (3.5 mm &), or untreated (control *). Ym values
are expressed as the percentage of cells with 500 or more artificial units of
fluorescence, calibrated at 50% for the control group at t=0 h. Data are the
average:SEM of three independent experiments. Valinomycin and troglita-
zone were used as controls for depolarization and hyperpolarization, respec-
tively.
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fluorescent dye 2’,7’-dichlorodihydrofluorescein diacetate
(DCFH-DH) (Figure 6).[34]
The results show that under normal culture conditions trypa-
nosomes generate a steady amount of ROS, which is greatly in-
creased in the presence of H2O2. The level of ROS was dose-de-
pendently increased over an incubation period of up to 2 h
with 20 and 22 (Figure 6A,B, respectively). As suggested previ-
ously for 4,[14b] 20 and 22 could be substrates of the electron-
transport chain, leading to cycle of reduction by glycerol-3-
phosphate dehydrogenase (G3PD) followed by reaction with
molecular oxygen and the production of ROS. In normal condi-
tions G3PD works like a shuttle between glycosomes and mito-
chondria, keeping the redox balance and feeding the respirato-
ry chain for the ATP production,[35] with TAO acting as electron
acceptor, oxidizing the ubiquinol pool formed in consequence
of G3PD activity.[36] Accordingly, the observed overproduction
of ROS is consistent with an ubiquinol-like reactivity for our hy-
brids.[37] This would cause both molecular and structural
damage to T. b. brucei mitochondria (see section on Transmis-
sion Electron Microscopy, below).[38]
CNSL-based hybrids cause damages of the mitochondria but
not the kinetoplast
Transmission electron microscopy (TEM) was used to study the
trypanosomes’ ultrastructure after exposure to compound 22
at 1VEC50 (7.6 mm) in order to visualize any damage to the mi-
tochondrion. Based on the information obtained from the ATP
and Ym determinations, TEM samples were taken after 4 and
8 h exposure to test compound, as “early” and “late” time
points to define the effects on cellular ultrastructure (Figure 7).
After 4 h of incubation with 20, some mitochondria presented
an irregular shape. Moreover, membranous, electron-light
structures had appeared in many mitochondria, resembling va-
cuoles (Figure 7, second row of images) ; no other ultrastructur-
al changes were evident, appearing to confirm the mitochond-
rion as a main target for CNSL-based hybrids in trypanosomes.
Indeed, 20 caused further ultrastructure abnormalities in the
Table 2. Investigation of the role of TAO in the trypanocidal activity of
test compounds.
Compd Control s427WT Control s427WT + 5 mm glycerol
EC50 [mm]
[a] EC50 [mm]
[a] RF[b] p value[c]
18 30.0:0.08 31.2:0.6 1.04 n.s.
19 16.8:0.06 16.3:0.4 0.97 n.s.
20 9.2:0.04 16.0:0.2 1.74 p<0.001
22 25.4:1.0 28.2:0.2 1.11 n.s.
SHAM[d] 86.3:0.4 58.9:0.6 0.68 p<0.001
[a] Values are the average:SEM of three independent determinations.
[b] Resistance factor. [c] Statistical significance was determined using Stu-
dent’s unpaired t-test ; n.s. : not significant. [d] Salicylhydroxamic acid.
Figure 6. Effect of A) 20 and B) 22 on ROS production in bloodstream forms
of T. b. brucei s427WT. Production of ROS was measured using the fluores-
cent indicator dye DCFH-DH. Cells incubated with 100 mm H2O2 (a) ; CNSL-
based hybrids were at: 2VEC50 (b), 1.25VEC50 (c), and 0.32VEC50 (d). Para-
sites incubated without test compound (e); plain assay buffer without cells
(f).
Figure 7. Ultrastructure TEM images of untreated (A) and treated (B, 4 h; C,
8 h) s427WT BSF with 22 at 1VEC50. m: mitochondrion, N: nucleus, F: flagel-
lum, k: kinetoplast, arrow: membranous structure within the mitochondrion
matrix. Scale bars : 1 mm.
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mitochondrial structure at 8 h, displaying damage to the mito-
chondrial membrane, and the presence of membranous and
dense vesicles within the matrix (Figure 7, third row). However,
the treated cells do not display any morphological alteration
to kinetoplasts, which completely maintain the original disk-
like structure.[39] Accordingly, this evidence stands for an exclu-
sive metabolic effect at mitochondrial level for the test com-
pounds, which do not interfere with both functioning and rep-
lication of kinetoplasts.
To confirm whether the CNSL-based hybrids exclusively
target the mitochondrial energetic pathway rather than the mi-
tochondrial kDNA, we decided to test compounds 4, 20 and
22 against the isometamidium-adapted ISMR1 cell line of
T. b. brucei in parallel with the parental cell line 427WT. As
ISMR1 is a dyskinetoplastic cell line, and thus highly resistant
to the drug isometamidium (ISM; Supporting Information Fig-
ure S2) and other kinetoplast-targeting drugs,[32] a primary
effect on energy metabolism rather than mitochondrial kDNA
should not result in resistance to the test compounds. Indeed,
compounds 4, 20 and 22 did not show a significant increase in
the EC50 values relative to the standard wild-type strain 427,
tested in parallel (Figure 8). These data exclude kDNA as a po-
tential target for our test hybrids, with the available data all
consistent with a mitochondrial target.
Although we had observed no toxicity of these naphthoqui-
none hybrids toward human cells, we next assessed whether
they might damage mitochondria in human cells. We therefore
determined the ATP content in treated and untreated HFF cell
line with a deliberately high concentration (200 mm) of 22. The
compound had only a very minor effect on cellular ATP levels,
even at this concentration, being approximately 26V trypano-
cidal EC50, although the effect became significant at 8 h of in-
cubation (p<0.05). Oligomycin exhibited a strong effect even
at 4 h (p<0.0.1) (Figure 9).
We also used TEM after exposure to the same concentration
of 22 (200 mm) at two different time points (4 and 12 h) in
order to analyze whether ultrastructural changes similar to
those in T. brucei could be observed. The TEM images reveal
that no morphological damage occurs to mitochondria in
human cells after treatment with even high concentrations of
22, nor were any other ultrastructural changes in the exposed
HFF cells visible (Figure 10). These results clearly show the ab-
sence of metabolic and structural toxic effects at the human
mitochondrial level, indicating a highly species-specific mode
of action for our CNSL-based hybrids.
Metabolomics analysis
Metabolomics has successfully been used to elucidate the
mode of action of drugs against T. brucei.[40] We therefore used
a metabolomics approach to further investigate the mode of
action of 22. T. b. brucei 427WT BSF were incubated with and
without 0.5VEC50 of 22 for 2 h to identify specific metabolic
changes caused by moderate exposure to the compound
(early effects). Samples were instantly cooled down to block
the intracellular metabolic activity, and processed to extract
the pool of intracellular metabolites. Analysis by LC–MS
showed a large number of metabolite differences between the
treated and untreated cells, but without a clear pattern desig-
nating a particular enzyme function or pathway, or indeed a
particular class of metabolites being affected apart from some
sphingolipid precursors which accumulated in the exposed
Figure 9. Determination of ATP content at various time points (0, 4, and 8 h)
in untreated and treated HFF cells with compound 22 (200 mm). Detection
was carried out using the firefly luciferase kit and measuring the levels of lu-
minescence to calculate the concentration of ATP (nm). Oligomycin
(2 mgmL@1) was used as positive control for decreasing ATP. Data are the
average:SEM of three independent experiments; *p<0.05, **p<0.01 (Stu-
dent’s t-test, unpaired).
Figure 10. TEM images of HFF cells cultured for 12 h in the absence (A) or
presence (B) of compound 20 at 200 mm. ER: endoplasmic reticulum, N: nu-
cleus, M: mitochondrion.
Figure 8. Comparison of the EC50 values for 20, 22, 4, and the control drug
isometamidium (ISM) obtained from the in vitro activity assay against blood-
stream trypomastigotes of T. b. brucei s427WT and T. b. brucei ISMR1. Data
are the average:SEM of three independent experiments ; ns : not significant,
***p<0.001 (Student’s t-test, unpaired).
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cells (Table 3), possibly indicating some direct or indirect inter-
ference in this pathway. These results are consistent with a
multi-target mode of action (as reported for 4)[14b] or the result
of general damage such as caused by ROS, affecting many cel-
lular functions at once.
Conclusions
In this report, we explore the use of a waste product of food
production, the CNSL, as a cheap and abundant source of new
anti-infective agents for use against NTD. The required chemis-
try is simple, accessible and easily scaled up, making the entire
production process highly affordable and local. Taken together,
the collected data suggest that, in the case of compounds 20
and 22, this CNSL hybridization strategy led to an increased
trypanocidal activity up to 10-fold relative to the parent com-
pound 4. This did not a priori signify that the new compounds
necessarily act similarly as 4, as the fusion with the CNSL-
based fragments affects both the pharmacokinetic and phar-
macodynamic features of the synthesized hybrids. In addition
to the contribution in target recognition, the long alkyl chain
clearly affects the physicochemical properties, which are deter-
minant for uptake by both target and host cells, delivery to mi-
tochondria, and interaction with molecular targets.
We present clear evidence for mitochondrial targeting in try-
panosomes, especially the TEM pictures are convincing, with
mitochondrial damage but no other ultrastructural changes
observed after just 4 h incubation with 1VEC50 of 22. It is quite
possible that this localized damage is linked to the observed
production of ROS. However, ATP depletion precedes mito-
chondrial abnormalities and the depolarization of Ym can be
observed within 30 min, and we propose that the hybrids, as
intended, exert more than one trypanocidal effect, consistent
with the complex return of the metabolomics experiment, (al-
though it was not possible to derive any clear conclusion from
the metabolomics data, at this point). All this does not exclude
a target inside the mitochondrion, but it is not (principally)
TAO or glycerol-3-phosphate dehydrogenase (G3PDH), which
together enable the re-oxidation of glycolysis-produced NAD+
via the cyanide-resistant, non-protonmotive oxidation of ubiq-
uinol by TAO.[41] This is because the activity of the hybrids was
not enhanced in the presence of glycerol. The target linked to
rapid ATP depletion could also be in glycosomes but we saw
no evidence of glycosomal damage in the TEM images, nor
consistent inhibition of GAPDH. The combination of cellular
damage by ROS, while depleting the ATP required for damage
repair, is likely to contribute to the rapid cell death observed
at just 1–2VEC50.
It is probably because the kinetoplast is not involved in the
trypanocidal action of these hybrid compounds that there is
no cross-resistance with diamidines (PMD and DA) and phen-
anthridine (ISM, ethidium) drugs. As these are the mainstay of
human (PMD) and especially veterinary trypanosomiasis treat-
ment, this is an important “plus” for this compound series.
Even more important, the compounds displayed excellent in
vitro selectivity over human cells ; in addition to the lack of
effect on growth rate of human fibroblasts, no effects on mito-
chondrial ultrastructure or ATP content, even at very high con-
centrations of compound were observed. This is especially en-
couraging in light of the severe toxicity of current HAT chemo-
therapy (Supporting Information Figure S1).[42]
In conclusion, while further rounds of optimization are re-
quired before these molecules can be turned into valuable
leads for trypanosomiasis, we have successfully demonstrated
that CNSL hybrids show promise as a template for the devel-
opment of anti-infective drugs on a sustainable basis. Impor-
tantly, the use of CNSL and its components for combating try-
panosomiasis could be of high importance and economically
feasible in developing countries that cultivate and process
cashew and, at the same time, represent endemic areas. Fur-
ther studies will focus on extending SAR, optimizing for T. con-
golense, and testing on veterinary trypanosome species that
are more closely related to T. brucei : T. evansi and T. equiper-
dum, which, being dyskinetoplastic, are not treatable with DA
or ISM, and not geographically restricted to the tsetse belt of
Africa.[6]
Experimental Section
Chemistry
General : All of the commercially available reagents and solvents
were used as purchased from Sigma–Aldrich and Tedia without fur-
ther purification. The cardanol mixture (2) was purchased from Re-
sibras (Fortaleza, Brazil). Reactions were followed by analytical thin-
layer chromatography (TLC), performed on precoated TLC plates
(layer 0.20 mm silica gel 60 with a fluorescent indicator UV254,
from Merck and F254 Silicycle plates). Developed plates were air-
dried and analyzed under a UV lamp (UV 254/365 nm) or visualized
by exposure to iodine stain. The oxidative cleavages were per-
formed using a Brasil Ozinio BrO3 ozonizer, whereas the catalytic
hydrogenations were performed using a Parr Shaker Hydrogena-
tion Apparatus 3916. Column chromatography purifications were
Table 3. Sphingolipid precursors elevated in trypanosomes treated with 22 versus untreated controls.[a]
m/z tR [min]
[a] Metabolite p value[b] Treated/Control
302.3046 5.0 sphinganine 0.034 1.654
538.5181 3.9 [SP (16:0)] N-(hexadecanoyl)sphing-4-enine 0.013 2.450
540.5348 5.1 [SP (16:0)] N-(hexadecanoyl)sphinganine 0.051 14.230
566.5504 3.8 [SP (18:0)] N-(octadecanoyl)sphing-4-enine 0.009 3.028
566.5493 5.6 [SP (18:0)] N-(octadecanoyl)sphing-4-enine 0.046 4.689
578.5528 3.9 sphing-8(Z)-enine-19:0, ceramide 0.018 6.708
[a] Retention time. [b] Statistical significance was determined using Student’s unpaired two-tailed t-test.
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performed using Sigma–Aldrich silica gel grade 9385, 60 a, 230–
400 mesh and Silicycle silica gel type G60, 60 a, 70–230 mesh.
Melting points were determined on a Quimis MQAPF 302 appara-
tus and are uncorrected. IR spectra were obtained on a PerkinElm-
er Spectrum BX infrared spectrophotometer. NMR experiments
were run on Varian VXR 400 (400 MHz for 1H; 100 MHz for 13C) and
on Bruker Avance DRX500 and DRX300 (500 and 300 MHz for 1H;
125 and 75 MHz for 13C, respectively) instruments. 1H and 13C NMR
spectra were acquired at 300 K using deuterated chloroform
(CDCl3) as solvent. Chemical shifts (d) are reported in parts per mil-
lion (ppm) relative to the residual solvent peak as internal refer-
ence, and coupling constants (J) are reported in hertz (Hz). The
spin multiplicities are reported as s= singlet, br s=broad singlet,
d=doublet, dd=doublet of doublet t= triplet, q=quartet, and
m=multiplet. Mass spectra were recorded on a Waters ZQ 4000
apparatus, and electrospray ionization (ESI) in positive mode was
applied. Compounds were named following IUPAC rules as applied
by ChemDraw Professional (version 15.0). All tested compounds
possess a purity of at least 95% as assessed by HPLC. HPLC param-
eters were the following: MeOH (eluent A) and H2O with 0.05% tri-
fluoroacetic acid (eluent B); flow rate 1.0 mLmin@1; elution type
isocratic with 50% of eluent A and 50% of eluent B; detection UV/
Vis Abs at 254 nm; Kinetex 5 mm EVO C18 100 a, LC Column 150V
4.6 mm (see section Compound Purity and Table S2 in the Support-
ing Information for details).
Synthesis of phenols 5–7
Natural CNSL extraction : In a Soxhlet extraction system were
added 150 g of cashew nutshell and absolute ethanol (400 mL).
The system was maintained at reflux for 4 h. Then, the collecting
flask was changed and a new extraction was carried out under the
same conditions. In both cases, the solvent was evaporated under
reduced pressure, providing 60 g of natural CNSL as a brown liquid
in 40% yield relative to the nutshell mass.
Mixture of anacardic acids (1) from natural CNSL : In a flask were
added 30 g of natural CNSL (&86.08 mmol), 15 g Ca(OH)2
(202.44 mmol) and methanol (180 mL) and water (30 mL). The reac-
tion system remained at reflux and agitation for 3 h. Then, the mix-
ture was cooled to room temperature and filtered. The solid ob-
tained was washed with ethyl acetate to remove the other compo-
nents of the CNSL. The calcium salts formed were treated with
50% hydrochloric acid solution to pH 1.0 to liberate the mixture of
anacardic acids, which were extracted with ethyl acetate (3V
50 mL). The combined organic phases were washed with brine and
dried over anhydrous sodium sulfate. After removal of the solvent
under reduced pressure, the mixture was purified on a silica gel
chromatography column, eluted in a mixture of hexane and 20%
ethyl acetate, affording the mixture of anacardic acids (1) as a
brown oil in 70% yield.
2-Hydroxy-6-pentadecylbenzoate (29): To a solution of heteroge-
neous mixture of anacardic acids 1 (5 g, 14.35 mmol for average
molecular wild-type 344) in ethanol (50 mL), was added with 10%
palladium on carbon (0.20 g, 2 mol%) and shaken in a Parr appara-
tus, under hydrogen atmosphere (60 psi) during 6 h. After, the re-
action mixture was filtered in a sintered funnel and the filtrate was
concentrated under reduced pressure. The residue was purified by
chromatography with silica gel (hexane and then hexane/ethyl ace-
tate 20%) as eluent, to afford the title compound 6 as a white
solid. Yield: 70%; mp: 81–83 8C. IR (KBr): n˜max=3326 (nOH) ; 2954
(nasCH3) ; 2920 (nasCH2) ; 2850 (nsCH2), 1610 (nC=O), 1560, 1542, 1498 and
1466 (nC=C) ; 1287 (nasC@O) ; 1086 cm
@1 (nsC@O).
1H NMR (300 MHz,
CDCl3): d=0.89 (t, J=6.5 Hz, 3H); 1.26 (m, 24H); 1.57–1.62 (m,
2H); 3.00 (t, J=7.7 Hz, 2H); 6.79 (d, J=7.4 Hz, 1H); 6.89 (d, J=
8.01 Hz, 1H); 7.37 ppm (t, J=7.9 Hz, 1H). 13C NMR (75 MHz, CDCl3):
d=14.3, 22.9, 29.6–30.0, 32.1, 32.2, 36.7, 110.6, 116.1, 123.0, 135.6,
148.1, 163.8, 176.5 ppm.
Methyl 2-hydroxy-6-pentadecylbenzoate (5): A mixture of 0.2 g
of 28 (0.574 mmol) and 1.5 mL of H2SO4 in methanol was stirred
and held at reflux for 18 h. After, the reaction was washed with
brine (10 mL), extracted with dichloromethane (3V10 mL) and
dried with anhydrous sodium sulfate. The solvent was evaporated
under reduced pressure and the product was purified by chroma-
tography on silica gel (hexane and then hexane/ethyl acetate 20%)
to afford the title compound 5 as a white solid. Yield: 86%. IR
(KBr): n˜max=3433 (nOH), 2917 (nas CH2), 2851 (nS CH2), 1663 (nC=O), 1451
(nC=C), 1250, 1203 cm
@1 (nas C@O).
1H NMR (500 MHz, CDCl3): d=0.89
(t, J=6.8 Hz, 3H), 1.27–1.32 (m, 29H), 1.51–1.55 (m, 2H), 2.89 (t, J=
7.8 Hz, 2H), 3.96 (s, 1H), 6.73 (d, J=7.3 Hz, 1H), 6.84 (d, J=8.1 Hz,
1H), 7.27–7.31 (m, 1H), 11.06 ppm (s, 1H). 13C NMR (125 MHz,
CDCl3): d=14.2, 22.9, 29.5–30.1, 32.1, 32.3, 36.8, 52.3, 112.0, 115.8,
122.6, 134.3, 146.4, 162.8, 172.1 ppm.
3-Pentadecylphenol (6): To a solution of heterogeneous mixture
of cardanols 2 (monoene, diene, and triene (10 g, 33.05 mmol for
average molecular wild-type 300) in ethanol (40 mL), was added
with 10% palladium on carbon (0.25 g, 2 mol%) and shaken in a
Parr apparatus, under hydrogen atmosphere (60 psi) during 4 h.
After, the reaction mixture was filtered in a sintered funnel and the
filtrate was concentrated under reduced pressure. The residue was
purified by chromatography with silica gel using a mixture of
hexane/dichloromethane (1:1) as eluent, to afford the title com-
pound 6 as a white solid. Yield: 90%; mp: 44–45 8C. 1H NMR
(500 MHz, CDCl3): d=0.92 (t, J=6.8 Hz, 3H), 1.29–1.33 (m, 24H),
1.60–1.61 (m, 2H), 2.58 (t, J=7.7 Hz, 2H), 6.67–6.69 (m, 2H), 6.79
(d, J=7.4 Hz, 1H), 7.16 ppm (t, J=7.7 Hz, 1H). 13C NMR (125 MHz,
CDCl3): d=14.3, 22.9, 29.6–29.9, 31.5, 32.2, 36.0, 112.8, 115.6, 121.2,
129.5, 145.2, 155.6 ppm.
3-(8-Hydroxyoctyl)phenol (7): An Erlenmeyer flask containing a so-
lution of 12 g of mixture of cardanols 2 (monoene, diene and
triene) (39.4 mmol) distilled acetic anhydride (12 mL) and phospho-
ric acid (12 drops) was placed inside an unmodified household mi-
crowave oven and irradiated for 3 min (3V1 min) at a power of
400 W. After, the residue was extracted with ethyl acetate (3V
15 mL) and the combined organic fractions washed with solution
of 5% sodium bicarbonate (20 mL), 10% hydrochloric acid solution
(20.0 mL), brine (20 mL), and dried over anhydrous sodium sulfate.
After evaporation of the solvent at reduced pressure, the reaction
mixture was purified by chromatography on a silica gel (dichloro-
methane) affording the desired compound in 73% yield. Then,
10.00 g of the mixture of acetylated cardanols was diluted with di-
chloromethane (20 mL) and methanol (20 mL) in a ozonolysis flask
of 250 mL. The flask was adapted to the ozonator with a stream of
ozone for one 1.5 h, in bath of dry ice/acetone. Next, the secon-
dary ozonide was reduced with 5.9 g of sodium borohydride
(158.7 mmol) in 60 mL of methanol. At the end of addition of
sodium borohydride, the reaction remained for 6 h under stirring.
Then, the mixture was acidified with concentrated hydrochloric
acid to pH 3, and it was extracted with ethyl acetate (3V30 mL).
The combined organic fractions were washed with brine (30 mL)
and dried over sodium sulfate. After evaporation of the solvent,
the product was purified by chromatography on silica gel (di-
chloromethane/chloroform, 5:5 and then chloroform/ethanol, 9:1)
leading to the title compound 7 as colorless oil. Yield: 79%. IR
(KBr): n˜max=3351, 2929, 2855, 1589, 1456 cm
@1. IV (KBr): n˜max=3351
(nOH) ; 2929 (nas CH2) ; 2855 (ns CH2) ; 1589, 1456 cm
@1 (nC=C).
1H NMR
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(300 MHz, CDCl3): d=1.30 (s, 8H), 1.53–1.59 (m, 4H), 2.54 (t, J=
7.6 Hz, 2H), 3.66 (t, J=6.6 Hz, 2H), 6.65 (dd, J=8.1 Hz, J=2.5 Hz,
1H), 6.67 (s, 1H), 6,71 (d, J=7.6 Hz, 1H), 7.19 ppm (d, J=7.8 Hz,
1H). 13C NMR (75 MHz, CDCl3): d=25.8, 29.2, 29.4, 29.5, 31.3, 32.7,
35.9, 63.2, 112.8, 115.6, 120.8, 129.5, 144.9, 156.0 ppm.
General procedure for the synthesis of CNSL-based hybrids (8–
22): To a solution of the proper phenol derivative (5–7) (0.1 mmol
and 0.3 mmol for 7) in dry DMF (0.04m), K2CO3 (0.1 mmol and
0.3 mmol for 7) was added. The resulting mixture was stirred for
0.5 h at room temperature. For phenol 7, the reaction was con-
ducted at 0 8C to avoid the formation of side products. Subse-
quently, the suitable 2-bromo-1,4-naphtoquinone (23–27) was
added (0.1–0.3 mmol) to the reaction mixtures, which were stirred
at room temperature for further 2–3 h. Then, LiCl 5% solution was
added (10 mL), whereas the reaction mixtures involving 26 and 27,
were previously acidified with a solution of 2n HCl (pH 5), until the
chemical toning changes from blue-green to orange. Next, the ob-
tained mixtures were extracted with ethyl acetate (10 mLV3). The
organic extracts were collected, dried over Na2SO4 and the solvent
was evaporated under vacuum. The crude residue was purified by
chromatography on silica gel and/or purified by crystallization,
when required.
Methyl 2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)oxy)-6-pentade-
cylbenzoate (8): The title compound was obtained according to
the general procedure using 5 and 23, and purified by chromatog-
raphy on silica gel with a mixture of petroleum ether/ethyl acetate
(9:1), as eluent. Compound 8 was obtained as a yellow waxy solid.
Yield: 61%. 1H NMR (400 MHz; CDCl3): d=0.85 (t, J=6.8 Hz, 2H),
1.23–1.28 (m, 27H), 2.66 (t, J=8.4 Hz, 2H), 3.77 (s, 3H), 5.96 (s, 1H),
6.95 (d, J=8.4 Hz, 1H), 7.18 (d, J=7.6 Hz, 1H), 7.39 (t, J=7.6 Hz,
1H), 7.72–7.75 (m, 2H), 8.04–8.06 (m, 1H), 8.15–8.16 ppm (m, 1H).
13C NMR (100 MHz; CDCl3): d=14.08, 22.65, 29.32, 29.34, 29.45,
29.50, 29.62, 29.66, 31.24, 31.89, 33.62, 52.30, 114.18, 119.04,
126.20, 126.67, 126.71, 127.76, 131.03, 131.10, 131.96, 133.48,
134.34, 143.91, 149.96, 160.16, 166.47, 179.40, 184.88 ppm. MS
(ESI+) m/z C33H42O5 : 541 [M+Na]
+ ; 557 [M+K]+ .
Methyl 2-((8-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)oxy)-6 pentadecylbenzoate (9): The title compound was ob-
tained according to the general procedure using 5 and 24, and pu-
rified by chromatography on silica gel with a mixture of ethyl ace-
tate/petroleum ether/toluene (6:3:1), as eluent. Compound 9 was
obtained as a yellow waxy solid. Yield: 60%. 1H NMR (400 MHz;
CDCl3): d=0.85 (t, J=7.2 Hz, 2H), 1.23–1.27 (m, 27H), 2.64 (t, J=
8 Hz, 2H), 3.76 (s, 3H), 4.00 (s, 3H), 5.87 (s, 1H), 6.92 (d, J=8 Hz,
1H), 7.15 (d, J=8 Hz, 1H), 7.24–7.28 (m, 1H), 7.37 (t, J=8.4 Hz, 1H)
7.61–7.70 ppm (m, 2H). 13C NMR (100 MHz; CDCl3): d=14.08, 22.65,
29.32, 29.35, 29.44, 29.50, 29.63, 29.66, 31.24, 31.89, 33.57, 52.32,
54.50, 112.19, 117.51, 118.83, 118.87, 119.06, 126.76, 127.54, 130.97,
134.28, 135.43, 143.71, 150.13, 160.18, 160.69, 166.52, 177.77,
184.85 ppm. MS (ESI+) m/z C34H44O6 : 571 [M+Na]
+ , 587 [M+K]+ .
Methyl 2-((5-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)oxy)-6-pentadecylbenzoate (10): The title compound was ob-
tained according to the general procedure using 5 and 25, and pu-
rified by chromatography on silica gel with a mixture of ethyl ace-
tate/petroleum ether/toluene (5:4:1), as eluent. Compound 10 was
obtained as a yellow waxy solid. Yield: 53%. 1H NMR (400 MHz;
CDCl3): d=0.84–0.87 (m, 2H), 1.23–1.28 (m, 27H), 2.65 (t, J=8 Hz,
2H), 3.75 (s, 3H), 3.98 (s, 3H), 5.89 (s, 1H), 6.94 (d, J=8.5 Hz, 1H),
7.16 (d, J=7.6 Hz, 1H), 7.31 (d, J=8.4 Hz, 1H), 7.38 (t, J=8 Hz, 1H),
7.66 (t, J=8 Hz, 1H), 7.83 ppm (d, J=7.2 Hz, 1H). 13C NMR
(100 MHz; CDCl3): d=14.10, 22.67, 29.33, 29.35, 29.47, 29.51, 29.63,
29.65, 29.67, 31.24, 31.90, 33.61, 52.26, 56.56, 116.37, 118.68,
119.06, 119.37, 119.61, 126.69, 127.55, 131.06, 133.32, 134.44,
143.79, 150.05, 158.16, 159.44, 166.55, 179.69, 184.47 ppm. MS
(ESI+) m/z C34H44O6 : 571 [M+Na]
+ , 587 [M+K]+ .
Methyl 2-((8-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)oxy)-
6-pentadecylbenzoate (11): The title compound was obtained ac-
cording to the general procedure using 5 and 26, and purified by
chromatography on silica gel with a mixture of petroleum ether/
ethyl acetate/toluene (7:2:1), as eluent. Compound 11 was ob-
tained as an orange–yellow waxy solid. Yield: 65%. 1H NMR
(400 MHz; CDCl3): d=0.84–0.87 (m, 2H), 1.23–1.28 (m, 27H), 2.66
(t, J=8 Hz, 2H), 3.79 (s, 3H), 5.95 (s, 1H), 6.95 (d, J=8 Hz, 1H), 7.19
(d, J=8 Hz,1H), 7.24–7.27 (m, 1H), 7.40 (t, J=8 Hz, 1H), 7.58–7.65
(m, 2H), 11.76 ppm (s, 1H). 13C NMR (100 MHz; CDCl3): d=14.09,
22.66, 29.33, 29.45, 29.50, 29.63, 29.64, 29.66,31.24, 31.90, 33.65,
52.35, 114.26, 114.78, 118.96, 124.05, 126.60, 127.90, 131.17, 131.98,
137.14, 144.00, 149.83, 159.80, 161.93, 166.42, 183.97, 184.29 ppm.
MS (ESI+) m/z C33H42O6 : 557 [M+Na]
+ , 573 [M+K]+ .
Methyl 2-((5-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)oxy)-
6-pentadecylbenzoate (12): The title compound was obtained ac-
cording to the general procedure using 5 and 27, and purified by
chromatography on silica gel with a mixture of petroleum ether/
ethyl acetate (8.5:1.5) as eluent. Compound 12 was obtained as an
orange–yellow solid. Yield: 30%. 1H NMR (400 MHz; CDCl3): d=
0.84–0.88 (m, 2H), 1.24–1.28 (m, 28H), 2.67 (t, J=8 Hz, 2H), 3.78 (s,
3H), 5.89 (s, 1H), 6.95 (d, J=8 Hz, 1H), 7.18–7.28 (m complex, 2H),
7.41 (t, J=8 Hz, 1H), 7.59 (t, J=8 Hz, 1H), 7.70 (d, J=8 Hz, 1H)
12.08 ppm (s, 1H). 13C NMR (100 MHz; CDCl3): d=14.08, 22.66,
29.34, 29.45, 29.50, 29.63, 29.66, 31.24, 31.89, 33.64, 52.36, 113.77,
114.22, 118.96, 119.59, 125.24, 126.59, 127.96, 131.01, 131.178,
135.64, 144.04, 149.84, 160.75, 161.10, 166.37, 167.537, 178.70,
190.80. MS (ESI+) m/z C33H42O6 : 557 [M+Na]
+ , 573 [M+K]+ .
2-(3-Pentadecylphenoxy)naphthalene-1,4-dione (13): The title
compound was obtained according to the general procedure
using 6 and 23, and purified by crystallization from EtOH/H2O.
Compound 13 was obtained as a yellow waxy solid. Yield: 21%.
1H NMR (400 MHz; CDCl3): d=0.89 (t, J=8 Hz, 2H), 1.27–1.34 (m,
27H), 2.65 (t, J=4 Hz, 2H), 5.98 (s, 1H), 6.95–6.97 (m, 2H), 7.14 (d,
J=8 Hz, 1H), 7.36 (t, J=4 Hz, 1H), 7.76–7.80 (m complex, 2H),
8.07–8.09 (m, 1H), 8.22–8.24 ppm (m, 1H). 13C NMR (100 MHz;
CDCl3): d=14.15, 14.16, 22.27, 29.24, 29.39, 29.47, 29.58, 29.68,
29.71, 29.72, 31.19, 31.95, 35.72, 113.27, 118.13, 120.88, 126.23,
126.75, 130.05, 131.11, 131.99, 133.52, 134.45, 145.96, 152.60,
160.64, 180.07, 185.11 ppm. MS (ESI+) m/z C31H40O3 : 483 [M+Na]
+ .
8-Methoxy-2-(3-pentadecylphenoxy)naphthalene-1,4-dione (14):
The title compound was obtained according to the general proce-
dure using 6 and 24, and purified by chromatography on silica gel
with a mixture of petroleum ether/ethyl acetate (6:4), as eluent.
Compound 14 was obtained as a yellow waxy solid. Yield: 65%.
1H NMR (400 MHz; CDCl3): d=0.84–0.87 (t, J=8 Hz, 2H), 1.23–1.27
(m, 27H), 2.60 (t, J=7.6 Hz, 2H), 4.02 (s, 3H), 5.86 (s, 1H), 6.88–6.90
(m, 2H), 7.08 (d, J=8 Hz, 1H), 7.26–7.32 (m, 2H), 7.64–7.71 ppm
(m, 2H). 13C NMR (100 MHz; CDCl3): d=14.08, 22.65, 29.19, 29.32,
29.41, 29.53, 29.63, 29.66, 31.13, 31.89, 35.68, 56.51, 111.38, 117.51,
118.13, 118.84, 118.96, 120.89, 126.48, 129.89, 134.31, 34.43, 145.77,
152.89, 160.21, 161.22, 178.33, 184.98 ppm. MS (ESI+) m/z C32H42O4 :
513 [M+Na]+ , 529 [M+K]+ .
5-Methoxy-2-(3-pentadecylphenoxy)naphthalene-1,4-dione (15):
The title compound was obtained according to the general proce-
dure using 6 and 25, and purified by chromatography on silica gel
with a mixture of petroleum ether/ethyl acetate (6:4), as eluent.
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Compound 15 was obtained as a yellow waxy solid. Yield: 30%.
1H NMR (400 MHz; CDCl3): d=0.84–0.87 (m, 2H), 1.23–1.27 (m,
27H), 2.60 (t, J=8 Hz, 2H), 3.97 (s, 3H), 5.87 (s, 1H), 6.90–6.92 (m,
2H), 7.08 (d, J=8 Hz, 1H), 7.29–7.31 (m, 2H), 7.66 (t, J=8 Hz, 1H),
7.85 ppm (d, J=8 Hz, 1H). 13C NMR (100 MHz; CDCl3): d=14.09,
22.66, 29.19, 29.32, 29.41, 29.52, 29.63, 29.66, 31.10, 31.89, 35.68,
56.54, 115.74, 118.09, 118.70, 119.38, 119.64, 120.84, 126.47, 129.92,
133.40, 134.39, 145.80, 152.70, 158.57, 159.40, 180.27, 180.51 ppm.
MS (ESI+) m/z C32H42O4 : 513 [M+Na]
+ , 529 [M+K]+ .
8-Hydroxy-2-(3-pentadecylphenoxy)naphthalene-1,4-dione (16):
The title compound was obtained according to the general proce-
dure using 6 and 26, and purified by crystallization from EtOH/
H2O. Compound 16 was obtained as an orange waxy solid. Yield:
45%. 1H NMR (400 MHz; CDCl3): d=0.86–0.89 (m, 2H), 1.25–1.31
(m, 27H), 2.63 (t, J=7.6 Hz, 2H), 5.95 (s, 1H), 6.92–6.94 (m, 2H),
7.12 (d, J=7.6 Hz, 1H), 7.28 (m, H), 7.35 (t, J=8 Hz, 1H), 7.58–7.66
(m, 2H), 11.79 ppm (s, 1H). 13C NMR (100 MHz; CDCl3): d=14.04,
22.63, 29.16, 29.30, 29.38, 29.50, 29.60, 29.64, 31.07, 31.87, 35.66,
113.86, 114.32, 117.94, 118.90, 120.69, 123.98, 126.79, 130.06,
132.01, 137.15, 146.02, 152.51, 160.23, 161.97,184.06, 184.78 ppm.
MS (ESI+) m/z C31H40O4 : 499 [M+Na]
+ , 515 [M+K]+ .
5-Hydroxy-2-(3-pentadecylphenoxy)naphthalene-1,4-dione (17):
The title compound was obtained according to the general proce-
dure using 6 and 27, and purified by chromatography on silica gel
with a mixture of petroleum ether/toluene/ethyl acetate (8.5:1:0.5),
as eluent. Compound 17 was obtained as an orange waxy solid.
Yield: 3%. 1H NMR (400 MHz; CDCl3): d=0.85 (t, J=7.2 Hz, 2H),
1.23–128 (m, 27H), 2.64 (t, J=7.6 Hz, 2H), 5.88 (s, 1H), 6.93–6.95
(m, 2H), 7.14 (d, J=8 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.36 (t, J=
8 Hz, 1H), 7.62 (t, J=8 Hz, 1H), 7.75 (d, J=8 Hz, 1H), 12.13 ppm (s,
1H). 13C NMR (100 MHz; CDCl3): d=14.05, 22.64, 29.16, 29.30,
29.39, 29.50, 29.61, 29.64, 31.07, 31.87, 35.65, 112.85, 114.19,
117.95, 119.59, 120.71, 125.24, 126.83, 130.05, 131.10, 135.56,
146.01, 152.53, 161.09, 161.19, 179.23, 190.90 ppm. MS (ESI+) m/z
C31H40O4 : 499 [M+Na]
+ .
2-(3-(8-Hydroxyoctyl)phenoxy)naphthalene-1,4-dione (18): The
title compound was obtained according to the general procedure
using 7 and 23, and purified by chromatography on silica gel with
a mixture of n-hexane/ethyl acetate (5:5), and then by crystalliza-
tion from n-hexane/EtOH. Compound 18 was obtained as an
orange-yellow waxy solid. Yield: 25%. 1H NMR (400 MHz; CDCl3):
d=1.32–1.52 (m, 10H), 1.53–1.61 (m, 6H), 2.63 (t, J=7.6 Hz, 2H),
3.63 (t, J=6.4, 2H), 5.96 (s, 1H), 6.93–6.95 (m, 2H), 7.11 (d, J=
7.6 Hz, 1H), d7.35 (t, J=8 Hz, 1H), 7.74–7.78 (m, 2H), 8.05–8.07 (m,
1H), 8.19–8.21 ppm (m, 1H). 13C NMR (100 MHz; CDCl3): d=14.09,
22.61, 25.64, 28.97, 29.24, 29.32, 31.01, 31.55, 32.72, 35.62, 62.96,
113.21, 118.10, 120.81, 126.18, 126.70, 126.75, 130.04, 131.07,
131.94, 133.48, 134.39, 145.78, 152.59, 160.60, 179.16, 185.07 ppm.
MS (ESI+) m/z C24H26O4 : 401 [M+Na]
+ .
2-(3-(8-Hydroxyoctyl)phenoxy)-8-methoxynaphthalene-1,4-dione
(19): The title compound was obtained according to the general
procedure using 7 and 24, and purified by chromatography on
silica gel with a mixture of ethyl acetate/petroleum ether/toluene/
EtOH (5.5:3:1:0.5). Compound 19 was obtained as an orange-
yellow waxy solid. Yield: 20%. 1H NMR (400 MHz; CDCl3): d=1.32
(s, 10H), 1.54–1.62 (m complex, 6H), 2.62 (t, J=7.6 Hz, 2H), 3.63 (t,
J=6.4 Hz, 2H), 4.04 (s, 3H), 5.87 (s, 1H), 6.91–6.92 (m, 2H), 7.19 (d,
J=7.6 Hz, 1H), 7.29–7.33 (m, 2H), 7.68–7.71 ppm (m, 2H). 13C NMR
(100 MHz; CDCl3): d=25.61, 28.94, 29.20, 29.27, 30.94, 32.74, 35.59,
56.50,62.96, 111.43, 117.59, 118.12, 118.85, 120.84, 126.44, 129.89,
134.36, 135.35, 145.64, 152.99, 160.25, 161.22, 178,23, 184.94 ppm.
MS (ESI+) m/z C25H28O5 : 431 [M+Na]
+ , 447 [M+K]+ .
2-(3-(8-Hydroxyoctyl)phenoxy)-5-methoxynaphthalene-1,4-dione
(20): The title compound was obtained according to the general
procedure using 7 and 25, and purified by chromatography on
silica gel with a mixture of ethyl acetate/n-hexane/toluene (7:2:1).
Compound 20 was obtained as an orange–yellow waxy solid.
Yield: 34%. Compound 20 was also synthesized from 7 (0.3 mmol),
25 (0.3 mmol), and K2CO3 (0.3 mmol) in dry DMSO (0.04m), and pu-
rified according to the above-reported procedure. Yield: 31%.
1H NMR (400 MHz; CDCl3): d=1.23–1.29 (m, 8H), 1.51–1.63 (m, 6H),
2.60 (t, J=7.6, 2H), 3.61 (t, J=6.8 Hz, 2H), 3.97 (s, 3H), 5.86 (s, 1H),
6.90–6.91 (m, 2H), 7.07 (d, J=7.6 Hz, 1H), 7.29–7.33 (m, 2H), 7.66
(t, J=8 Hz, 1H), 7.84–7.86 ppm (m, 1H). 13C NMR (100 MHz; CDCl3):
d=25.62, 28.94, 29.24, 29.32, 30.97, 32.75, 35.59, 56.53,62.96,
115.44, 118.14, 118.72, 119.33, 119.65, 120.85, 126.52, 129.97,
133.38, 134.43, 145.66, 152.69, 158.61, 159.41, 180.27, 184.67 ppm.
MS (ESI+) m/z C25H28O5 : 431 [M+Na]
+ , 447 [M+K]+ .
8-Hydroxy-2-(3-(8-hydroxyoctyl)phenoxy)naphthalene-1,4-dione
(21): The title compound was obtained according to the general
procedure using 7 and 26, and purified by chromatography on
silica gel with a mixture of ethyl acetate/n-hexane/toluene (5:4:1).
Compound 21 was obtained as an orange–yellow waxy solid.
Yield: 13%. 1H NMR (400 MHz; CDCl3): d=1.26–1.32 (m, 11H), 1.54–
1.64 (m complex, 8H), 2.64 (t, J=7.6 Hz, 2H), 3.63 (t, J=6.6 Hz,
2H), 5.95 (s, 1H), 6.93–6.95 (m, 2H), 7.13 (d, J=7.6 Hz, 1H), 7.2–
7.29 (m, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.59–7.67 (m, 2H), 11.80 ppm
(s, 1H). 13C NMR (100 MHz; CDCl3): d=25.64, 28.98, 29.24, 29.32,
31.01, 32.74, 35.62, 63.00, 113.82, 114.32, 118.02, 118.94, 120.72,
124.02, 126.83, 130.11, 131.99, 137.21, 145.91, 152.49, 160.27,
161.98, 184.12, 184.79 ppm. MS (ESI+) m/z C24H26O5 : 417 [M+Na]
+ ,
433 [M+K]+ .
5-Hydroxy-2-(3-(8-hydroxyoctyl)phenoxy)naphthalene-1,4-dione
(22): The title compound was obtained according to the general
procedure using 7 and 27, and purified by chromatography on
silica gel with a mixture of ethyl acetate/n-hexane/toluene (5:4:1).
Compound 22 was obtained as an orange–yellow waxy solid.
Yield: 28%. 1H NMR (400 MHz; CDCl3): d=1.30–1.40 (m, 12H),
1.52–1.59 (m complex, 5H), 2.61 (t, J=7.6 Hz, 2H), 3.61 (t, J=
6.6 Hz, 2H), 5.87 (s, 1H), 6.91–6.92 (m, 2H), 7.11 (d, J=7.6 Hz, 1H),
7.24–7.33 (m, 2H), 7.58 (t, J=8 Hz, 1H), 7.71 (d, J=7.2 Hz, 1H),
12.09 ppm (s, 1H). 13C NMR (100 MHz; CDCl3): d=25.65, 29.00,
29.25, 31.02, 32.73, 35.62, 63.01, 112.82, 114.17, 118.01, 119.65,
120.72, 125.30, 126.87, 130.10, 131.07, 135.62, 145.91, 152.49,
161.07, 161.19, 179.26, 190.53 ppm. MS (ESI+) m/z C24H26O5 : 417
[M+Na]+ , 433 [M+K]+ .
Prediction of physicochemical properties and pan-assay inter-
ference compounds (PAINS) analysis
The online server FAFDrugs4[43] (http://fafdrugs3.mti.univ-paris-di-
derot.fr) was used to predict physicochemical properties of 8–22
(Supporting Information Table S1). These include: number of rotat-
able bonds, hydrogen-bond acceptors (HBAs), hydrogen-bond
donors (HBDs), MW, logP, logD (at pH 7), topological polar surface
area (tPSA), flexibility, and aqueous solubility (logSw). FAFDrugs4
[43]
was also used to screen 8–22 for known classes of pan-assay inter-
ference compounds (PAINS). As expected, 8–22 were flagged as
potential PAINS, due to the presence of the quinone sub-structure
and the long alkyl chain. However, despite the potential for these
compounds to interfere with non-cellular assays,[44] we found no
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activity against isolated TbGAPDH protein. Furthermore, the fact
that the trypanocidal activity is limited to quinones with C8 alkyl
chain (18–22) points to a high degree of specificity and interaction
with well-defined target(s) rather than a nonspecific interaction. In
addition, 20 and 22 showed severalfold lower trypanocidal activity
when evaluated against T. congolense (IL3000WT). These observa-
tions led us to believe that the current subset does not behave as
PAINS.
Biological evaluation
Organisms and culture media : Only bloodstream trypomastigotes
of T. b. brucei were used throughout this study. The drug-sensitive
wild-type strain Trypanosoma brucei brucei Lister 427 (427WT)[25a]
was used alongside three multidrug-resistant strains: B48, ISMR1,
and aqp2/aqp3-KO. B48 was created from 427WT after deletion of
the TbAT1 gene, encoding for the P2 drug transporter,[25b] and
adaptation to increasing concentrations of PMD.[45] The aqp2/aqp3-
KO strain was generated from wild-type T. b. brucei 2T1 cells after
knockout of the locus encoding for the aquaglyceroporin 2 and 3
channels, resulting in melarsoprol–pentamidine cross-resist-
ance.[21,46] ISMR1 is an ISM-resistant clone obtained from T. b. brucei
427WT that lost their kinetoplast DNA and express an FoF1-ATP syn-
thase mutation.[32] All the T. b. brucei strains were cultured as de-
scribed[47] in standard HMI-9 medium, supplemented by 10% of
heat-inactivated fetal bovine serum (FBS), 14 mLL@1 of b-mercap-
toethanol, and 3.0 gL@1 of sodium hydrogen carbonate (pH 7.4).
Parasites were cultured in vented flasks at 37 8C and 5% CO2 at-
mosphere and they were passaged every 3 days. Bloodstream
forms of T. congolense savannah-type strain IL3000 were cultured
in basal MEM medium, supplemented by 10% fresh goat serum,
14 mL of b-mercaptoethanol, 800 mL of 200 mm glutamine solution,
and 10 mL of penicillin/streptomycin solution per liter of medium
(pH 7.3).[48] T. congolense were cultured in six-well plates at 34 8C
and 5% CO2.
In vitro drug susceptibility assay : The drug susceptibilities of
bloodstream-form trypanosomes of T. b. brucei 427WT, B48, aqp2/
aqp3-KO and ISMR1 strains were determined by using the resazur-
in (Alamar blue) viability indicator dye following a previously de-
scribed protocol,[49] slightly adapted for T. congolense. In brief, the
assays were performed in 96-well plates with 2V105 cells per well
for T. b. brucei or 5V105 cells per well for T. congolense, in their re-
spective culture media. First, 200 mL of test compounds’ solutions
(400 mm, in T. brucei or T. congolense medium as appropriate) was
added to the first well of each 12-well row, from which doubling
dilutions were conducted over one row per test compound. Trypa-
nosomes (100 mL in each well) were added and the plates were in-
cubated for 48 h at 37 8C and 5% CO2, followed by addition of
20 mL Alamar blue solution (125 mgmL@1 of resazurin sodium salt
(Sigma–Aldrich) in phosphate-buffered saline (PBS)) followed by
24 h of incubation at 37 8C and 5% CO2. PMD (Sigma–Aldrich) (for
427WT, B48, aqp2/aqp3-KO), DA (Sigma–Aldrich; for T. congolense)
and ISM (gift from Merial France) (for ISMR1) were used as trypano-
cidal positive controls. Fluorescence was detected using a FLUOstar
Optima (BMG Labtech, Durham, NC, USA) at wavelength of 540 nm
(excitation), 590 nm (emission). EC50 values were calculated by non-
linear regression using an equation for a sigmoidal dose–response
curve with variable slope using Prism 5.0 (GraphPad Software Inc. ,
San Diego, CA, USA).
Growth curve : T. b. brucei 427WT cells were grown to mid-log-
phase in standard HMI-9/FBS medium distributed in in six-well
plates at 1V105 cellsmL@1 and incubated with two different con-
centrations of test compounds (EC50, 2VEC50) for 48 h at 37 8C and
5% CO2. Untreated parasites, used as control, were grown in paral-
lel. The cells were counted by using hemocytometer cell counter
(cell count/mLV104) at 0, 2, 4, 8, 12, 24, 28, 32, 36, 48 h of incuba-
tion. Each experiment was performed as two independent repli-
cates, and each sample was counted at least twice.
Cytotoxicity assay on human foreskin fibroblast (HFF): Toxicity of
test compounds to mammalian cells was carried out using the re-
sazurin assay previously described[31] with slight modifications as
follows. HFF cells were grown in a culture medium containing
500 mL of Dulbecco’s modified Eagle’s medium (DMEM; Sigma),
50 mL newborn calf serum (NBCS; Gibco), 5 mL penicillin/strepto-
mycin (Gibco), and 5 mL of l-Glutamax (200 nm, Gibco), at 37 8C
and 5% CO2 in vented flasks and passaged at 80–85% of conflu-
ence. For the cytotoxicity assay, cells were suspended at 3V105
cellsmL@1 and 100 mL aliquots were added to each well of a 96-
well plate. The plate was incubated at 37 8C and 5% CO2 for 24 h
to allow cell adhesion. Serial test compounds dilution was per-
formed in a different 96-well plate and 100 mL of each dilution was
transferred to each well containing cells, resulting in exposure of
cells to 200–0.2 mm of test compound. Phenylarsine oxide (Sigma–
Aldrich) was used as positive control and drug-free incubation as
negative control. The plates were incubated at 37 8C and 5% CO2
for an additional 30 h, at which point 10 mL of resazurin solution
(125 mgmL@1 in PBS) was added, followed by a final incubation for
24 h. The plates were read and the data analyzed as described
above for the trypanosome assay.
ATP assay on T. b. brucei and HFF cells : Changes in cellular ATP
levels due to the exposure of trypanosomes to the test com-
pounds (0.5VEC50) were monitored using the Molecular Probes
ATP Determination Kit (A22066, Invitrogen Detection Technologies),
based on the luciferin–luciferase bioluminescent enzymatic reac-
tion. Bloodstream trypomastigote cultures of T. brucei s427WT were
incubated with and without test compound, and, at each predeter-
mined incubation time, 107 cells of each sample were transferred
into a microfuge tube and centrifuged at 2000Vg for 10 min at
4 8C. The pellet was washed twice with 1 mL of 50 mm Tris·HCl
(pH 7.4) containing 0.1 mm DTT, and then resuspended in 200 mL
of the same buffer. The cells were lysed by sonication on ice (twice
for 10 s separated by 30 s), using a Soniprep 150 (MSE) at 8 mm
amplitude. The samples were centrifuged at 10000Vg for 10 min
at 4 8C and the supernatant was collected, instantly frozen in liquid
nitrogen, and stored at @80 8C. Oligomycin (2.0 mgmL@1) was used
as positive control. ATP levels were quantified using the contents
of the kit following the manufacturer’s instructions; 90 mL of stan-
dard reaction solution was added to each well of a 96-well plate
and the background luminescence was recorded in a FLUOstar
OPTIMA fluorimeter; 10 mL of each sample was then added to each
well. The plate was incubated at 28 8C for 15 min and the lumines-
cence was measured, including a standard curve with an ATP con-
centration ranging from 1 nm to 1 mm to allow the calculation of
the ATP concentrations in each sample. The ATP content was mea-
sured at 0, 0.5, 1, 2, 4, 8 and 12 h of incubation with test sample.
The same procedure was used to determine the ATP content of
HFF cells, using 200 mm of the test compounds for incubation
times of 0, 4, and 8 h, 1V106 HFF cells per sample and a centrifu-
gation speed for pelleting the cells of 800Vg for 5 min. Oligomycin
(2 mgmL@1) was used as a positive control as described.[50]
Mitochondrial membrane potential assay on T. b. brucei :
Changes in mitochondrial membrane potential (Ym) after incuba-
tion of trypanosomes with the test compounds were determined
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using fluorescence-activated cell sorting (FACS) with the indicator
dye tetramethylrhodamine ethyl ester (TMRE), as described[34] with
minor modifications. Cell suspensions of T. b. brucei 427WT trypo-
mastigotes were incubated at 0.5VEC50 with test compound and
1V107 cells were transferred at each time point (0, 0.5, 1, 2, 4, 8
and 12 h) into a microfuge tube and centrifuged at 2000Vg for
10 min at room temperature. The pellet was washed once in 1 mL
of PBS (pH 7.4) and resuspended in 1 mL of PBS containing 200 nm
TMRE; the cells then were incubated at 37 8C for 30 min and subse-
quently placed on ice for another 30 min before analysis on a
Becton Dickinson FACSCalibur using a FL2-height detector, and
CellQuest and FlowJo software. Valinomycin (Sigma–Aldrich;
100 nm) and troglitazone (Sigma–Aldrich; 10 mm) were used as
controls for mitochondrial membrane depolarization and positive
hyperpolarization, respectively.[51]
Transmission electron microscopy assay on T. b. brucei and HFF
cells : TEM of bloodstream trypomastigotes (427WT) and of HFF
was performed essentially as previously described.[52] Briefly, cell
cultures were adjusted to 2.5V106 cellsmL@1 and incubated in the
presence or absence of test compounds at EC50. Cells were fixed
overnight at 4 8C in 2.5% glutaraldehyde and 4% paraformalde-
hyde in 0.1m phosphate buffer (pH 7.4). Samples were washed
with 0.1m phosphate buffer (pH 7.4), post-fixed in 1% osmium
tetroxide for 1 h on ice, and washed with the phosphate buffer.
Cells were next incubated in 0.5% uranyl acetate solution for
30 min, washed with distilled water and dehydrated in increasing
concentrations of acetone (30, 50, 70, 90 and 100%). Cells were
embedded in epoxy resin; thin sections of 50–60 nm were ob-
served in a Tecnai T20 (FEI) at 200 kV.
Reactive oxygen species (ROS) assay on T. b. brucei : The produc-
tion of ROS when T. b. brucei 427WT trypomastigotes incubated
with different concentration (2.5VEC50 ; 1.25VEC50 ; 0.3VEC50) of
test compound was assessed using the indicator dye 2,7-dichloro-
dihydrofluorescein diacetate (DCFH-DH; Sigma–Aldrich). This assay
was performed in a 96-well black-bottomed well plate; 200 mL of
each test compound solution, at 5VEC50 in assay buffer pH 7.3,
was added to the well in the first column of the plate and dou-
bling dilutions were carried out across the row, after which 3V106
cell in 100 mL of assay buffer were added to each well, immediately
followed by 2 mL of 1 mm DCFH-DH, under minimal light condi-
tions. The plates were incubated in a FLUOstar OPTIMA fluorimeter
at 37 8C 5% CO2 and the fluorescence was monitored at 485 nm
for the excitation, 520 nm for the emission for 3 h, taking readings
of each well every 2 min. Three wells were included in the plate as
controls : 1) 3V106 cells per well in assay buffer without test com-
pound; 2) 3V106 cells per well in assay buffer with 2 mL of 10 mm
H2O2 ; 3) assay buffer without cells and test compound.
Metabolomics assay in T. b. brucei : The experiment was per-
formed to detect changes in the intracellular metabolic pathway in
T. b. brucei 427WT BSF after 2 h incubation with the most active
test compound, at a concentration of 0.5VEC50, and compared
with a DMSO drug free control. Parasites were grown to 1.5V106
cellsmL@1 in order to have a mid-log-phase culture at the end of
the incubation time. At the end of the incubation, the cell density
was adjusted and 1V108 cells were transferred to a 50 mL centri-
fuge tube. The samples were quenched by rapidly cells cooling to
4 8C in a dry ice/ethanol bath and centrifuged at 1250Vg for
10 min at the same temperature. 10 mL of supernatant (spent
medium) was collected, 200 mL of CMW (chloroform/methanol/
water 1:4:1) was added and the mixture stored at @80 8C until LC–
MS analysis. The rest of the supernatant was discarded; the cell
pellet was transferred to a microfuge tube and centrifuged at
4500 rpm for 5 min at 4 8C. The pellet was washed once in 1 mL
PBS at 4 8C and resuspended in 200 mL of CMW extraction solvent
at 4 8C. The samples were shaken at 4 8C for 1 h to break up the
pellet and allow the complete extraction of intracellular metabo-
lites, followed by centrifugation at 13000 rpm for 10 min at 4 8C.
180 mL of supernatant was collected in an LC–MS vial. For each
biological replicate, 15 mL from each sample were all combined in
the same MS vial; this pooled sample served as a quality control.
All samples were gassed with Ar before sealing and stored at
@80 8C. All the samples were analyzed with LC–MS. The experiment
was conducted in three independent biological replicates, each an-
alyzed in duplicate (two technical replicates).
LC–MS analysis and data extraction : Samples were randomly
placed in the autosampler tray and the LC–MS experiment was
performed on an Accela 600 HPLC system combined with an Exac-
tive (Orbitrap) mass spectrometer from Thermo Fisher Scientific
(Hemel Hempstead, UK). In separate runs, 10 mL of sample was in-
jected onto a HiChrom Ltd. (Reading, UK) ZIC-pHILIC column (150V
4.6 mm, 5 mm particle size). The LC–MS system was run in binary
gradient mode; a flow rate of 0.3 mLmin@1 was used and samples
were kept in a vial tray set at 3 8C. The gradient conditions were as
follows: (A) 20 mm ammonium carbonate pH 9.2, (B) acetonitrile;
0 min 80% B; 30 min 20% B; 36 min 20% B, 37 min 80% B; 46 min
80% B. The ESI interface was operated in positive and negative ion
switching mode, with +4.0 kV of spray voltage for positive mode
and @3.5 kV for negative mode. The temperature of the ion-trans-
fer capillary was 270 8C and sheath and auxiliary gas were set at 57
and 17 arbitrary units, respectively. The full scan range of both pos-
itive and negative modes was set at 75 to 1200 m/z with AGC
target and resolution as Balanced and High (1E6 and 50000), re-
spectively. Prior to analysis, mass calibration was performed for
both ESI modes using the standard Thermo Calmix solution. The
mass spectrometry data was extracted by using m/z Mine 2.20[53]
and the masses were searched against an in-house database.
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